UNEARNED REVENUE |
9 Months Ended |
|---|---|
Sep. 30, 2025 | |
| Revenue Recognition and Deferred Revenue [Abstract] | |
| UNEARNED REVENUE |
Note 7. UNEARNED REVENUE
The Company engaged in an observational study of CyPath® Lung with the U.S. Department of Defense (“DOD”). A total of 70 CyPath® Lung units were ordered and shipped. However, in compliance with FASB ASC 606, the performance obligation was complete for only 40 units as of September 30, 2025. The performance obligation is deemed complete after samples have been collected, processed, and analyzed and results communicated to patients. The unearned revenue balance amounted to $24,404 as of September 30, 2025, and December 31, 2024.
During third quarter 2025, the Company engaged with Veteran Administration (“VA”) medical centers to purchase CyPath® Lung tests. A total of 20 tests were ordered and shipped. However, in compliance with FASB ASC 606, the performance obligation was complete for only 4 tests as of September 30, 2025. The performance obligation is deemed complete after samples have been collected, processed, and analyzed and results communicated to patients. The unearned revenue balance amounted to $13,511 as of September 30, 2025.
|
| X | ||||||||||
- Definition The entire disclosure for deferred revenues at the end of the reporting period, and description and amounts of significant changes that occurred during the reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef
|
| X | ||||||||||
- References No definition available.
|